Biosciences
Our researchers in have a rich legacy of collaboration with government agencies and industry partners that improve health outcomes and well-being around the world. SRI Biosciences projects range from high-impact, early-stage research to drug co-development with pharmaceutical and biotech companies.
-
Expanding cancer immunotherapy by exploiting recall immunity – a new co-therapy option for checkpoint inhibitor
SRI International has developed a novel immunotherapy that is capable of delivering previously encountered antigenic peptides specifically to cancer cells and facilitating their presentation through the MHC class I pathway.
-
Immunology is coming to the rescue
SRI scientist explores how to tame and leverage the human immune system to prevent allergies and fight disease
-
SRI introduces DiaCyt™ CNS drug-delivery platform at 2021 JP Morgan Conference
Novel peptide-based technology delivers molecular cargo through the blood brain barrier, enabling CNS drug discovery and therapeutic delivery
-
The mental health impact of COVID-19 restrictions
How did pandemic isolation and pandemic-related changes affect individuals around the globe?
-
How SRI’s AI technology is changing the way healthcare is delivered
Governments around the world have encouraged healthcare providers to utilize Telehealth to safely care for patients
-
SRI awarded $107 million NIAID-DAIDS contract to provide preclinical services for HIV therapeutics
SRI International has been awarded a contract from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases and the Division of AIDS to support research and product development for human immunodeficiency virus (HIV), Mycobacterium tuberculosis (MTB) complex, and hepatitis B and C viruses (HBV/HCV).
-
SRI International awarded $40 million NICHD contract for pre-clinical development of new male and female contraceptive products
SRI International has been awarded a Biological Testing Facility contract to complete discovery and preclinical development of new contraceptive compounds.
-
Solving for sleep
SRI’s Human Sleep Research Program is conducting groundbreaking research to address modern sleep challenges
-
SRI International awarded $4.3M from DARPA to create rapid response therapeutic manufacturing system
Extension of SynFini synthetic chemistry platform could accelerate availability ofnew treatments in pandemic and other emergency health situations MENLO PARK, Calif. – October 6, 2020 – SRI International has been awarded $4.3 million from the Defense Advanced Research Projects Agency (DARPA) to create ProSyn™, an agile, rapidly deployable extension of SynFini™, SRI’s fully automated synthetic…
-
SRI receives NSF grant to create new viral classification system
SRI International has been awarded a National Science Foundation (NSF) grant through the Grants for Rapid Response (RAPID) program. RAPID is a mechanism used by the NSF to provide funds for urgent research that addresses unexpected disasters or events such as the COVID-19 pandemic. SRI scientists will use the RAPID grant to develop a first-of-its-kind…
-
SRI research scientists discuss new opportunities for large-scale data collection through consumer sleep technology
Consumer sleep technology (CST) is a fast-paced industry, and little is known about the accuracy and reliability of consumer sleep-tracking devices
-
What if you gave cancer the measles?
SRI has created a novel platform that could significantly expand the benefit of immunotherapies by “infecting” cancer cells